Integrase inhibitor prodrugs: Approaches to enhancing the Anti-HIV activity of β-Diketo acids

Molecules

Volumn 20, Issue 7, 2015, Pages 12623-12651

  Nair, Vasu ^a   Okello, Maurice ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Antiviral activity; Hiv 1 integrase inhibitors; Prodrugs

Indexed keywords

INTEGRASE; INTEGRASE INHIBITOR; OXOACID; PRODRUG; PYRIDONE DERIVATIVE;

CELL MEMBRANE PERMEABILITY; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROLYSIS; IC50; METABOLISM; MOLECULAR DOCKING; MONONUCLEAR CELL; PATHOLOGY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE; VIROLOGY;

BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; DRUG DESIGN; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; HYDROLYSIS; INHIBITORY CONCENTRATION 50; KETO ACIDS; LEUKOCYTES, MONONUCLEAR; MOLECULAR DOCKING SIMULATION; PRODRUGS; PYRIDONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84938395278     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules200712623     Document Type: Review

References (73)

1. Frankel, A.D.; Young, J.A.T. HIV-1: Fifteen proteins and an RNA. Annu. Rev. Biochem. 1998, 67, 1-25.
2. Trono, D.; Van Lint, C.; Rouzioux, C.; Verdin, E.; Barre-Sinoussi, F.; Chun, T.W.; Chomont, N. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010, 329, 174-180.
3. Nair, V.; Chi, G. HIV integrase inhibitors as therapeutic agents in AIDS. Rev. Med. Virol. 2007, 17, 277-295.
4. Nair, V.; Chi, G.; Ptak, R.; Neamati, N. HIV integrase inhibitors with nucleobase scaffolds: Discovery of a highly potent anti-HIV agent. J. Med. Chem. 2006, 49, 445-447.
5. Pommier, Y.; Johnson, A.A.; Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 2005, 4, 236-248.
6. Nair, V. Novel inhibitors of HIV integrase: The discovery of potential anti-HIV therapeutic agents. Front. Med. Chem. Online 2005, 2, 3-20.
7. Summa, V.; Petrocchi, A.; Bonelli, F.; Crescenzi, B.; Donghi, M.; Ferrara, M.; Fiore, F.; Gardelli, C.; Paz, O.G.; Hazuda, D.J.; et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 2008, 51, 5843-5855.
8. Laufer, R.; Paz, O.G.; di Marco, A.; Bonelli, F.; Monteagudo, E.; Summa, V.; Rowley, M. Quantitative prediction of human clearance guiding the development of raltegravir (MK-0518, Isentress) and related HIV integrase inhibitors. Drug Metab. Dispos. 2009, 37, 873-883.
9. Garvey, E.P.; Johns, B.A.; Gartland, M.J.; Foster, S.A.; Miller, W.H.; Ferris, R.G.; Hazen, R.J.; Underwood, M.R.; Boros, E.E.; Thompson, J.B.; et al. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob. Agents Chemother. 2008, 52, 901-908.
10. Min, S.; Song, I.; Borland, J.; Chen, S.G.; Lou, Y.; Fujiwara, T.; Piscitelli, S.C. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob. Agents Chemother. 2010, 54, 254-258.
11. Klibanov, O.M. Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. Curr. Opin. Investig. Drugs 2009, 10, 190-200.
12. Asante-Appiah, E.; Skalka, A.M. HIV-1 integrase: Structural organization, conformational changes, and catalysis. Adv. Virus Res. 1999, 52, 351-369.
13. Esposito, D.; Craigie, R. HIV integrase structure and function. Adv. Virus Res. 1999, 52, 319-333.
14. Liao, C.Z.; Marchand, C.; Burke, T.R.; Pommier, Y.; Nicklaus, M.C. Authentic HIV-1 integrase inhibitors. Future Med. Chem. 2010, 2, 1107-1122.
15. Hare, S.; Gupta, S.S.; Valkov, E.; Engelman, A.; Cherepanov, P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010, 464, 232-236.
16. Nair, V. HIV integrase as a target for antiviral chemotherapy. Rev. Med. Virol. 2002, 12, 179-193.
17. Moss, D.M.; Neary, M.; Owen, A. The role of drug transporters in the kidney: Lessons from tenofovir. Front. Pharmacol. 2014, 5, 248, doi:10.3389/fphar.2014.00248.
18. De Clercq, E. A Cutting-edge view on the current state of antiviral drug development. Med. Res. Rev. 2013, 33, 1249-1277.
19. Hurwitz, S.J.; Schinazi, R.F. Prodrug strategies for improved efficacy of nucleoside antiviral inhibitors. Curr. Opin. HIV AIDS 2013, 8, 556-564.
20. Gulick, R. HIV treatment 2020: What will it look like? J. Int. AIDS Soc. 2014, 17, doi:10.7448/IAS.17.4.19528.
21. Walji, A.M.; Sanchez, R.I.; Clas, S.D.; Nofsinger, R.; Ruiz, M.L.; Li, J.; Bennet, A.; John, C.; Bennett, D.J.; Sanders, J.M.; et al. Discovery of MK-8970: An acetal carbonate prodrug of Raltegravir with enhanced colonic absorption. Chem. Med. Chem. 2015, 10, 245-252.
22. Sofia, M.J. Prodrugs in the treatment of viral diseases. RSC Drug Discov. Ser. 2013, 32, 421-450.
23. De Clercq, E. New approaches toward anti-HIV chemotherapy. J. Med. Chem. 2005, 48, 1297-1313.
24. Mazumder, A.; Uchida, H.; Neamati, N.; Sunder, S.; Jaworska-Maslanka, M.; Wickstrom, E.; Zeng, F.; Jones, R.A.; Mandes, R.F.; Chenault, H.K.; et al. Probing interactions between viral DNA and human immunodeficiency virus type 1 integrase using dinucleotides. Mol. Pharmacol. 1997, 51, 567-575.
25. Taktakishvili, M.; Neamati, N.; Pommier, Y.; Pal, S.; Nair, V. Recognition and inhibition of HIV integrase by novel dinucleotides. J. Am. Chem. Soc. 2000, 122, 5671-5677.
26. Hazuda, D.J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J.A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287, 646-650.
27. Wai, J.S.; Egbertson, M.S.; Payne, L.S.; Fisher, T.E.; Embrey, M.W.; Tran, L.O.; Melamed, J.Y.; Langford, H.M.; Guare, J.P.; Zhuang, L.G.; et al. 4-aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J. Med. Chem. 2000, 43, 4923-4926.
28. Marchand, C.; Zhang, X.C.; Pais, G.C.G.; Cowansage, K.; Neamati, N.; Burke, T.R.; Pommier, Y. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J. Biol. Chem. 2002, 277, 12596-12603.
29. Hazuda, D.J.; Young, S.D.; Guare, J.P.; Anthony, N.J.; Gomez, R.P.; Wai, J.S.; Vacca, J.P.; Handt, L.; Motzel, S.L.; Klein, H.J.; et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004, 305, 528-532.
30. Grobler, J.A.; Stillmock, K.; Hu, B.H.; Witmer, M.; Felock, P.; Espeseth, A.S.; Wolfe, A.; Egbertson, M.; Bourgeois, M.; Melamed, J.; et al. Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. USA 2002, 99, 6661-6666.
31. Goldgur, Y.; Craigie, R.; Cohen, G.H.; Fujiwara, T.; Yoshinaga, T.; Fujishita, T.; Sugimoto, H.; Endo, T.; Murai, H.; Davies, D.R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Proc. Natl. Acad. Sci. USA 1999, 96, 13040-13043.
32. Billich, A. S-1360 Shionogi-GlaxoSmithKline. Curr. Opin. Investig. Drugs 2003, 4, 206-209.
33. Yoshinaga, T.; Sato, A.; Fujishita, T. S-1360: In vitro activity of a new HIV-1 integrase inhibitor in clinical development. In Proceeding of the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 24-28 February 2002; p. 55.
34. Pannecouque, C.; Pluymers, W.; Van Maele, B.; Tetz, V.; Cherepanov, P.; de Clercq, E.; Witvrouw, M.; Debyser, Z. New class of HIV integrase inhibitors that block viral replication in cell culture. Curr. Biol. 2002, 12, 1169-1177.
35. Pluymers, W.; Pais, G.; Van Maele, B.; Pannecouque, C.; Fikkert, V.; Burke, T.R.; de Clercq, E.; Witvrouw, M.; Neamati, N.; Debyser, Z. Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives. Antimicrob. Agents Chemother. 2002, 46, 3292-3297.
36. Pais, G.C.G.; Zhang, X.C.; Marchand, C.; Neamati, N.; Cowansage, K.; Svarovskaia, E.S.; Pathak, V.K.; Tang, Y.; Nicklaus, M.; Pommier, Y.; et al. Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. J. Med. Chem. 2002, 45, 3184-3194.
37. Bacchi, A.; Carcelli, M.; Compari, C.; Fisicaro, E.; Pala, N.; Rispoli, G.; Rogolino, D.; Sanchez, T.W.; Sechi, M.; Neamati, N. HIV-1 IN strand transfer chelating inhibitors: A focus on metal binding. Mol. Pharm. 2011, 8, 507-519.
38. Mazumder, A.; Neamati, N.; Sundar, S.; Owen, J.; Pommier, Y. Retroviral integrase: A novel target in antiviral drug development and basic in vitro assays with purified enzyme in. In Antiviral Methods and Protocols; Kinchington, D., Schinazi, R., Eds.; Humana: Totowa, NJ, USA, 1999; Volume 24, pp. 327-338.
39. Marchand, C.; Johnson, A.A.; Karki, R.G.; Pais, G.C.G.; Zhang, X.C.; Cowansage, K.; Patel, T.A.; Nicklaus, M.C.; Burke, T.R.; Pommier, Y. Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S). Mol. Pharmacol. 2003, 64, 600-609.
40. Beare, K.D.; Coster, M.J.; Rutledge, P.J. Diketoacid inhibitors of HIV-1 integrase: From L-708,906 to raltegravir and beyond. Curr. Med. Chem. 2012, 19, 1177-1192.
41. Huang, M.; Grant, G.H.; Richards, W.G. Binding modes of diketo-acid inhibitors of HIV-1 integrase: A comparative molecular dynamics simulation study. J. Mol. Graph. Model. 2011, 29, 956-964.
42. Vandegraaff, N.; Kumar, R.; Hocking, H.; Burke, T.R.; Mills, J.; Rhodes, D.; Burrell, C.J.; Li, P. Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: Putative inhibitors of HIV-1 integrase. Antimicrob. Agents Chemother. 2001, 45, 2510-2516.
43. Rosemond, M.J.C.; St John-Williams, L.; Yamaguchi, T.; Fujishita, T.; Walsh, J.S. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: Role of human liver cytosolic aldo-keto reductases. Chem. Biol. Interact. 2004, 147, 129-139.
44. Zhang, X.C.; Pais, G.C.G.; Svarovskaia, E.S.; Marchand, C.; Johnson, A.A.; Karki, R.G.; Nicklaus, M.C.; Pathak, V.K.; Pommier, Y.; Burke, T.R. Azido-containing aryl beta-diketo acid HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 1215-1219.
45. Costi, R.; Di Santo, R.; Artico, M.; Roux, A.; Ragno, R.; Massa, S.; Tramontano, E.; La Colla, M.; Loddo, R.; Marongiu, M.E.; et al. 6-aryl-2,4-dioxo-5-hexenoic acids, novel integrase inhibitors active against HIV-1 multiplication in cell-based assays. Bioorg. Med. Chem. Lett. 2004, 14, 1745-1749.
46. Di Santo, R.; Costi, R.; Roux, A.; Artico, M.; Lavecchia, A.; Marinelli, L.; Novellino, E.; Palmisano, L.; Andreotti, M.; Amici, R.; et al. Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: Design, synthesis, biological activities, and mechanism of action. J. Med. Chem. 2006, 49, 1939-1945.
47. Long, Y.Q.; Jiang, X.H.; Dayam, R.; Sanchez, T.; Shoemaker, R.; Sei, S.; Neamati, N. Rational design and synthesis of novel dimeric diketoacid-containing inhibitors of HIV-1 integrase: Implication for binding to two metal ions on the active site of integrase. J. Med. Chem. 2004, 47, 2561-2573.
48. Zeng, L.F.; Jiang, X.H.; Sanchez, T.; Zhang, H.S.; Dayam, R.; Neamati, N.; Long, Y.Q. Novel dimeric aryldiketo containing inhibitors of HIV-1 integrase: Effects of the phenyl substituent and the linker orientation. Bioorg. Med. Chem. 2008, 16, 7777-7787.
49. Cox, A.G.; Nair, V. Novel HIV integrase inhibitors with anti-HIV activity: Insights into integrase inhibition from docking studies. Antivir. Chem. Chemother. 2006, 17, 343-353.
50. Chi, G.C.; Nair, V.; Semenova, E.; Pommier, Y. A novel diketo phosphonic acid that exhibits specific, strand-transfer inhibition of HIV integrase and anti-HIV activity. Bioorg. Med. Chem. Lett. 2007, 17, 1266-1269.
51. Nair, V.; Uchil, V.; Neamati, N. beta-Diketo acids with purine nucleobase scaffolds: Novel, selective inhibitors of the strand transfer step of HIV integrase. Bioorg. Med. Chem. Lett. 2006, 16, 1920-1923.
52. Kukhar, V.P.; Hudson, H.R. Aminophosphonic and Aminophosphinic Acids, Chemistry and Biological Activity; John Wiley and Sons, Ltd: Chichester, UK, 2000.
53. Sekine, M.; Kume, A.; Nakajima, M.; Hata, T. A new method for acylation of enolates by means of dialkyl acylphosphonates as acylating agents. Chem. Lett. 1981, 10, 1087-1090.
54. Holmquist, C.R.; Roskamp, E.J. A selective method for the direct conversion of aldehydes into beta-keto-esters with ethyl diazoacetate catalyzed by Tin(II) Chloride. J. Org. Chem. 1989, 54, 3258-3260.
55. Karaman, R.; Goldblum, A.; Breuer, E.; Leader, H. Acylphosphonic acids and methyl hydrogen acylphosphonates-physical and chemical-properties and theoretical calculations. J. Chem. Soc. Perkin Trans. 1 1989, 4, 765-774.
56. Seo, B.I.; Uchil, V.R.; Okello, M.; Mishra, S.; Ma, X.H.; Nishonov, M.; Shu, Q.N.; Chi, G.C.; Nair, V. Discovery of a potent HIV integrase inhibitor that leads to a prodrug with significant anti-HIV activity. ACS Med. Chem. Lett. 2011, 2, 877-881.
57. Urban, J.J.; Vontersch, R.L.; Famini, G.R. Effect of fluorine substitution on phenol acidities in the gas-phase and in aqueous-solution - A computational study using continuum solvation models. J. Org. Chem. 1994, 59, 5239-5245.
58. Resnati, G. Synthesis of chiral and bioactive fluoroorganic compounds. Tetrahedron 1993, 49, 9385-9445.
59. DiMagno, S.G.; Sun, H.R. The strength of weak interactions: Aromatic fluorine in drug design. Curr. Top. Med. Chem. 2006, 6, 1473-1482.
60. Hare, S.; Maertens, G.N.; Cherepanov, P. 3′-Processing and strand transfer catalysed by retroviral integrase in crystallo. EMBO J. 2012, 31, 3020-3028.
61. Boros, E.E.; Burova, S.A.; Erickson, G.A.; Johns, B.A.; Koble, C.S.; Kurose, N.; Sharp, M.J.; Tabet, E.A.; Thompson, J.B.; Toczko, M.A. A scaleable synthesis of methyl 3-amino-5-(4-fluorobenzyl)-2-pyridinecarboxylate. Org. Process Res. Dev. 2007, 11, 899-902.
62. Singh, B.; Bacon, E.R.; Lesher, G.Y.; Robinson, S.; Pennock, P.O.; Bode, D.C.; Pagani, E.D.; Bentley, R.G.; Connell, M.J.; Hamel, L.T.; et al. Novel and potent Adenosine 3′,5′-cyclic phosphate phosphodiesterase-III inhibitors-Thiazolo[4,5-B][1,6]naphthyridin-2-ones. J. Med. Chem. 1995, 38, 2546-2550.
63. Kowalski, P. Reactions of 2-aminopyridine with benzyl-chloride - benzylation of pyridine ring. Pol. J. Chem. 1984, 58, 959-960.
64. Nair, V.; Turner, G.A.; Chamberlain, S.D. Novel approaches to functionalized nucleosides via palladium-catalyzed cross coupling with organostannanes. J. Am. Chem. Soc. 1987, 109, 7223-7224.
65. Nair, V.; Turner, G.A.; Buenger, G.S.; Chamberlain, S.D. new methodologies for the synthesis of C-2 functionalized hypoxanthine nucleosides. J. Org. Chem. 1988, 53, 3051-3057.
66. Jiang, X.H.; Song, L.D.; Long, Y.Q. Highly efficient preparation of aryl beta-diketo acids with tert-butyl methyl oxalate. J. Org. Chem. 2003, 68, 7555-7558.
67. Uchil, V.; Seo, B.; Nair, V. A novel strategy to assemble the beta-diketo acid pharmacophore of HIV integrase inhibitors on purine nucleobase scaffolds. J. Org. Chem. 2007, 72, 8577-8579.
68. Kassahun, K.; McIntosh, I.; Cui, D.; Hreniuk, D.; Merschman, S.; Lasseter, K.; Azrolan, N.; Iwamoto, M.; Wagner, J.A.; Wenning, L.A. Metabolism and disposition in humans of raltegravir (MK-0518), an Anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab. Dispos. 2007, 35, 1657-1663.
69. Ortiz de Montellano, P.R. Cytochrome P450: Structure, Mechanism, and Biochemistry, 3rd ed.; Kluwer Academic/Plenum: New York, NY, USA, 2005.
70. Baranczewski, P.; Stanczak, A.; Sundberg, K.; Svensson, R.; Wallin, A.; Jansson, J.; Garberg, P.; Postlind, H. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol. Rep. 2006, 58, 453-472.
71. Chauret, N.; Gauthier, A.; Martin, J.; NicollGriffith, D.A. In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metab. Dispos. 1997, 25, 1130-1136.
72. Williams, J.A.; Hyland, R.; Jones, B.C.; Smith, D.A.; Hurst, S.; Goosen, T.C.; Peterkin, V.; Koup, J.R.; Ball, S.E. Drug-drug interactions for UDP-glucuronosyltransferase substrates: A pharmacokinetic explanation for typically observed low exposure (AUC(i)/AUC) ratios. Drug Metab. Dispos. 2004, 32, 1201-1208.
73. Okello, M.O.; Mishra, S.; Nishonov, M.; Mankowski, M.K.; Russell, J.D.; Wei, J.; Hogan, P.A.; Ptak, R.G.; Nair, V. A novel anti-HIV active integrase inhibitor with a favorable in vitro cytochrome P-450 and uridine 5′-diphospho-glucuronosyltransferase metabolism profile. Antivir. Res. 2013, 98, 365-372.